References
- Pommier JD, Ben Lasfar N, Van Grunderbeeck N, Burdet C, Laouénan C, Rioux C, et al. Complications following intravesical Bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients. Infect Dis 2015;47:729–735.
- Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al.; European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013;64:639–53.
- Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, et al. Bladder cancer. J Natl Compr Canc Netw 2013;11:446–75.
- Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder; results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69–76.
- Sylvester RJ, van der Meijden AP, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group. The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:423–8.
- Witjes JA, Palou J, Soloway M, Lamm D, Brausi M, Spermon JR, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. European Urology Supplements 2008;7:667–74.
- Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled multicenter study. J Urol 2006;176:935–9.